

Unactivated media: No drug
Unactivated media: Compound 1
Activated media: No drug
Activated media: Compound 1
Melanocyte Proliferation
(% confluence)
45
40
35
30
25
20
15
10
0
8
16
24
32
40
48
Hours
***
*
*P < 0.05
***P < 0.001

FIG. 1



Unactivated media: No drug
Unactivated media: Compound 1
Activated media: No drug
Activated media: Compound 1
Protein T cell media
pg/ml
12000
8000
4000
1000
800
600
400
200
0
IFNγ
IL-10
IL-13
IL-2
IL-4
IL-6
CXCL10
IFN-interferon
IL-interleukin
CXCL10-Interferon gamma-induced protein 10 (IP-10)

FIG. 2




FIG. 3A FIG. 3B FIG. 3C FIG. 4




FIG. 5A

FIG. 5B

FIG. 5C



• Male and women 18 to 75 years of age with non-segmental vitiligo
• % Vitiligo-affected BSA:
• Total body ≥ 8%
• Face ≥ 0.5%
• VASI score:
• Total body ≥ 8
• Face ≥ 0.5
• N ≈ 160
Randomization
Week
0
Day 1
Placebo-controlled period (24 weeks)
Extension period (24 weeks)
Placebo QD (n ~ 40)
Compound 1 Dose A QD (n ~ 40)
Compound 1 Dose C QD (n ~ 40)
Compound 1 Dose B QD (n ~ 40)
Compound 1 Dose C QD
(n ≈ 120)
Compound 1 Dose B QD (n ~ 40)
Visits every 4 weeks
Visits every 4 weeks
24
Primary endpoint
52
EOT
4-week safety follow-up
56
EOS

FIG. 6



Unactivated media: No drug
Activated media: No drug
Activated media: Ruxolitinib
Melanocyte Proliferation
(% confluence)
45
40
35
30
25
20
15
10
0
8
16
24
32
40
48
Hours
**
**
**P < 0.01
Unactivated media: No drug
Activated media: No drug
Activated media: Ruxolitinib
Protein T cell media
pg/ml
1500
1000
500
160
120
80
40
0
IFNγ
IL-10
IL-13
IL-2
IL-4
IL-5
IL-6
CXCL10
IFN-interferon
IL-interleukin
CXCL10-Interferon
gamma-induced protein 10 (IP-10)

FIG. 7

FIG. 8



Unactivated media: No drug
Activated media: No drug
Activated media: Ruxolitinib
Protein T cell media
pg/ml
0
20
40
60
80
IL-8

FIG. 9A



Unactivated media: No drug
Activated media: No drug
Activated media: Ruxolitinib
Protein T cell media
pg/ml
0
10
20
30
40
50
LIF

FIG. 9B



Unactivated media: No drug
Activated media: No drug
Activated media: Ruxolitinib
Protein Melanocyte media
pg/ml
2000
1750
1500
500
400
300
200
100
0
IFN
CXCL10
IL-6
IL-13
IL-10
IFN - interferon
IL - interleukin
CXCL10 - interferon gamma-induced protein 10 (IP

FIG. 10




FIG. 11A

FIG. 11B